Hi,
I’ve been an investor for many years and have heard every conf call. Regarding this 5% group, I don’t trust them, and I don’t think anyone should. So it really doesn’t matter what they say, if they’re not credible. As mentioned, former employees Caracciolo and Pestell are part of this group.
Thank you Ohm, for reminding the message board that it was Caracciolo who brought the worthless Prostate test, which has been shelved, and gave Pestell 8 million shares. Pestell was appointed as the CMO (I don’t think he actually has his Board license in the USA, which made no sense to be the CMO.)
“We are very pleased to expand and strengthen our relationship with Dr. Pestell...,” said Anthony Caracciolo, CytoDyn’s Chairman. “As we separately announced today, we have signed a non-binding letter of intent for the proposed acquisition of ProstaGene.” (7/12/18)
This was an absurd decision from Caracciolo to acquire the Prostate test. In addition, I remember during the couple conference calls Caracciolo actually was a part of, I was totally unimpressed by Caraccoilo’s speaking ability and grasp of situations investors brought up. He kept us in the dark for way over a year, and essentially no progress happened with the company. Furthermore, Pestell was terminated by the Board.
So why should we believe this group?
Besides these two individuals, this 5% group includes 2 pizza shop owners, a realtor, a bunch of “consultants.” What possible earth-shattering wisdom will they offer that could make any difference to the value of the company? There is nothing to gain and everything to lose. Regardless of what they advise, they’re not trustworthy. Their true motives cannot be trusted.
I’m very concerned they will take over and put their people in place to sell out cheap to Big Pharma, or some other horrible situation will occur.
At this point, the only thing that really counts are well designed trials and positive data. There’s been tremendous progress this year. There are multiple Covid trials, NASH trial, Cancer basket, BLA submission. There’s more money in the bank than ever in Cytodyn’s history. Let’s be stay the course! We will have data readouts in the very near future and that will mean everything!
Certainly, I’ve been frustrated by Nader’s communication, however he has improved. Also, Dr. Jay vouches for his trustworthiness (on his recent podcast) which is important.
I am very impressed and encouraged by Dr. Scott Kelly. I believe he is a good man, a patient advocate, and he goes the extra mile for Covid patients trying to get Lernonlimab. He’s smart, articulate, knows the science. Listen to the TNBC cancer presentation. He formed the scientific advisory board with top notch physician scientists and leaders in medicine.
As a shareholder, I want minimum dilution, to explore and ultimately get approval for a wide variety of indications, grow the company organically and not selling out cheap to Big Pharma! These align with the goals of Nader, Kelly, and the Board. There’s been tremendous progress this last year and I want to keep the momentum. The FDA letter and this 5% group are bumps in the road, but just gotta keep moving forward, and fully reject this 5% group.
I’ve been an investor for many years and have heard every conf call. Regarding this 5% group, I don’t trust them, and I don’t think anyone should. So it really doesn’t matter what they say, if they’re not credible. As mentioned, former employees Caracciolo and Pestell are part of this group.
Thank you Ohm, for reminding the message board that it was Caracciolo who brought the worthless Prostate test, which has been shelved, and gave Pestell 8 million shares. Pestell was appointed as the CMO (I don’t think he actually has his Board license in the USA, which made no sense to be the CMO.)
“We are very pleased to expand and strengthen our relationship with Dr. Pestell...,” said Anthony Caracciolo, CytoDyn’s Chairman. “As we separately announced today, we have signed a non-binding letter of intent for the proposed acquisition of ProstaGene.” (7/12/18)
This was an absurd decision from Caracciolo to acquire the Prostate test. In addition, I remember during the couple conference calls Caracciolo actually was a part of, I was totally unimpressed by Caraccoilo’s speaking ability and grasp of situations investors brought up. He kept us in the dark for way over a year, and essentially no progress happened with the company. Furthermore, Pestell was terminated by the Board.
So why should we believe this group?
Besides these two individuals, this 5% group includes 2 pizza shop owners, a realtor, a bunch of “consultants.” What possible earth-shattering wisdom will they offer that could make any difference to the value of the company? There is nothing to gain and everything to lose. Regardless of what they advise, they’re not trustworthy. Their true motives cannot be trusted.
I’m very concerned they will take over and put their people in place to sell out cheap to Big Pharma, or some other horrible situation will occur.
At this point, the only thing that really counts are well designed trials and positive data. There’s been tremendous progress this year. There are multiple Covid trials, NASH trial, Cancer basket, BLA submission. There’s more money in the bank than ever in Cytodyn’s history. Let’s be stay the course! We will have data readouts in the very near future and that will mean everything!
Certainly, I’ve been frustrated by Nader’s communication, however he has improved. Also, Dr. Jay vouches for his trustworthiness (on his recent podcast) which is important.
I am very impressed and encouraged by Dr. Scott Kelly. I believe he is a good man, a patient advocate, and he goes the extra mile for Covid patients trying to get Lernonlimab. He’s smart, articulate, knows the science. Listen to the TNBC cancer presentation. He formed the scientific advisory board with top notch physician scientists and leaders in medicine.
As a shareholder, I want minimum dilution, to explore and ultimately get approval for a wide variety of indications, grow the company organically and not selling out cheap to Big Pharma! These align with the goals of Nader, Kelly, and the Board. There’s been tremendous progress this last year and I want to keep the momentum. The FDA letter and this 5% group are bumps in the road, but just gotta keep moving forward, and fully reject this 5% group.
44
